Aesthetic firms are betting that a growing pool of patients experiencing loose skin and facial volume loss from GLP-1 obesity drugs will fuel a new wave of demand, as the sector heads into first-quarter earnings this week. Companies, including Apyx Medical (APYX.O), InMode (INMD.O), Establishment Labs (ESTA.O), and Evolus (EOLS.O), are targeting patients dealing with the after-effects of rapid weight loss, as the obesity drug market is projected to reach $100 billion in annual sales by 2030. With some weight-loss drugs now available at lower out-of-pocket costs, consumers are also using the savings to invest in aesthetic treatments, boosting demand for these companies.
Read the full article: Weight-Loss Revolution Sparks New Appetite for Aesthetics Firms //
Source: https://www.reuters.com/business/healthcare-pharmaceuticals/weight-loss-revolution-sparks-new-appetite-aesthetics-firms-2026-05-04/